TransMedics Group Inc vs Williams Companies Inc — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Williams Companies Inc trades at $75.15 (market cap $92.75B). The key difference: Williams Companies Inc is far larger — about 30.3× TransMedics Group Inc's market cap, and Williams Companies Inc pays a 2.77% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WMB | |
|---|---|---|
Market Cap | $3.06B | $92.75B |
Sector | Technology | Energy |
52-Week High | $150.42 | $79.40 |
52-Week Low | $61.99 | $56.51 |
Enterprise Value | $3.46B | $123.38B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Williams Companies (WMB) trades at $75.83, up 2.27% with strong analyst support (79% buy ratings) and a $88.14 consensus target. The stock shows bullish technical momentum above key support at $74, supported by recent acquisitions and stable dividend payments. Fundamentals reveal robust profitability with 63.26% gross margins and 25.18% net income margin, though valuation multiples remain elevated with P/E at 30.21.
WMB offers exposure to growing natural gas infrastructure demand with recent $5.5 billion Momentum Midstream acquisition expanding Gulf Coast presence. Risks include regulatory challenges as seen with NJ pipeline permit reversal and elevated debt levels at 52% debt-to-asset ratio. The stock presents growth potential through LNG export expansion but faces execution risks on major projects.
Trailing returns across standard periods
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →